Background
==========

A number of studies have suggested that CD8 T cells play an important role in control of HIV/SIV replication. Recently, it has been shown that CD8 T cells taken from HIV-positive long term non-progressors are more efficiently cytotoxic than those from rapid progressors. We therefore endeavored to test vaccine adjuvants for their ability to generate antigen specific CD8 T cells with a significant capacity for cytolytic degranulation. The adjuvants tested for this purpose were IL-12 and IL-28B.

Methods
=======

Animals were immunized using either a multi-clade consensus HIV Gag construct or multi-clade consensus HIV Pol construct, with or without adjuvant. All animals received electroporation during the immunization process using the Cellectra device manufactured by VGX Pharmaceuticals.

Results
=======

In mice, the inclusion of either adjuvant increased antigen-specific IFNgamma ELISpot numbers 3 to 4 fold over antigen alone and lead to significant differences in antigen-specific Perforin upregulation. Both IL-12 and IL-28B were able to induce 100% protection from death associated with infection following a lethal influenza challenge, suggesting both adjuvants may induce potent cellular immune responses. However, only IL-28B lead to a significant increase in degranulation as measured by CD107a expression when compared with antigen alone, suggesting this cytokine has more potent cytotoxicity-inducing affects than IL-12. In macaques, both IL-12 and IL-28B augmented IFNgamma ELISpot results two-fold over antigen alone. Similarly to what was seen in mice, however, only IL-28B induced a statistically significant amount of degranulation as measured by CD107a expression when compared to animals that did not receive adjuvant.

Conclusion
==========

While both adjuvants augmented antigen-specific IFNgamma ELISpot responses, only IL-28B was able to induce statistically significant amounts of cytolytic degranulation. Therefore, further study of IL-28B as an adjuvant for cytotoxicity is warranted.
